66 related articles for article (PubMed ID: 17354106)
1. Molecular mechanisms of pancreatic cancer and potential targets of treatment.
Aho U; Zhao X; Löhr M; Andersson R
Scand J Gastroenterol; 2007 Mar; 42(3):279-96. PubMed ID: 17354106
[No Abstract] [Full Text] [Related]
2. Comment on "Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway".
Wang W; Sun W; Zhang L
J Immunol; 2009 Aug; 183(4):2203; author reply 2203-4. PubMed ID: 19661264
[No Abstract] [Full Text] [Related]
3. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.
Choi BH; Kim CG; Lim Y; Shin SY; Lee YH
Cancer Lett; 2008 Jan; 259(1):111-8. PubMed ID: 18006147
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis.
Kang MJ; Ryu BK; Lee MG; Han J; Lee JH; Ha TK; Byun DS; Chae KS; Lee BH; Chun HS; Lee KY; Kim HJ; Chi SG
Gastroenterology; 2008 Dec; 135(6):2030-42, 2042.e1-3. PubMed ID: 18824170
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.
Wang J; Yang L; Yang J; Kuropatwinski K; Wang W; Liu XQ; Hauser J; Brattain MG
Cancer Res; 2008 May; 68(9):3152-60. PubMed ID: 18451140
[TBL] [Abstract][Full Text] [Related]
6. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways in pancreatic cancer.
Reddy SA
Cancer J; 2001; 7(4):274-86. PubMed ID: 11561604
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
10. Promising molecular targets in ovarian cancer.
Blagden S; Gabra H
Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
[TBL] [Abstract][Full Text] [Related]
11. Alpha-chaconine-reduced metastasis involves a PI3K/Akt signaling pathway with downregulation of NF-kappaB in human lung adenocarcinoma A549 cells.
Shih YW; Chen PS; Wu CH; Jeng YF; Wang CJ
J Agric Food Chem; 2007 Dec; 55(26):11035-43. PubMed ID: 18044836
[TBL] [Abstract][Full Text] [Related]
12. Targeting the EGFR and the PKB pathway in cancer.
Klein S; Levitzki A
Curr Opin Cell Biol; 2009 Apr; 21(2):185-93. PubMed ID: 19216065
[TBL] [Abstract][Full Text] [Related]
13. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells.
Wu M; Min C; Wang X; Yu Z; Kirsch KH; Trackman PC; Sonenshein GE
Cancer Res; 2007 Jul; 67(13):6278-85. PubMed ID: 17616686
[TBL] [Abstract][Full Text] [Related]
14. Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells.
Cascio S; Ferla R; D'Andrea A; Gerbino A; Bazan V; Surmacz E; Russo A
J Cell Physiol; 2009 Oct; 221(1):189-94. PubMed ID: 19492417
[TBL] [Abstract][Full Text] [Related]
15. FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1.
Hayashi H; Nakagami H; Takami Y; Koriyama H; Mori M; Tamai K; Sun J; Nagao K; Morishita R; Kaneda Y
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):909-14. PubMed ID: 19325137
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitory effect of AG490 on invasion and metastasis of human pancreatic cancer cells in vitro].
Huang C; Qiu ZJ; Cao J; Huang KJ; Zhang F; Jiang T; Zhu L; Liu J
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):890-3. PubMed ID: 17533737
[TBL] [Abstract][Full Text] [Related]
17. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
18. [New targets of anticancer drugs and their pathways].
Yin LL; Wang YQ
Zhonghua Nan Ke Xue; 2002; 8(3):221-3. PubMed ID: 12478851
[TBL] [Abstract][Full Text] [Related]
19. Targets, trials, and travails in pancreas cancer.
Izeradjene K; Hingorani SR
J Natl Compr Canc Netw; 2007 Nov; 5(10):1042-53. PubMed ID: 18053428
[TBL] [Abstract][Full Text] [Related]
20. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
Saif MW
JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
